drugset / Trial / NCT02325492

Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study

NCT02325492

Phase 2 Terminated 10 enrolled Galmed Pharmaceuticals Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a one center, Phase IIa, randomized, double blind, placebo controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects 18 to 75 years of age, with newly formed cholesterol gallstones in their gallbladder following bariatric surgery confirmed by gallbladder ultrasound ..

Timeline

Start
2014-10
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aramchol Other / unclassified 400 mg Oral
Subject Aramchol Other / unclassified 600 mg Oral

Indications